(Q33365473)

English

Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

Leishmania donovani

object named as

Leishmania donovani

1 reference

based on heuristic

inferred from title

4

object named as

Prashant Khare

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Shraddha Kumari

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mukesh Samant

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pragya Misra

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Brijesh Sisodia

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ajit K Shasany

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anuradha Dube

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

30 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

45

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5700-5711

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leishmaniasis: current status of vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Leishmaniasis: current situation and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

T-cell and cytokine responses in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Immunobiology of experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Dichotomy of protective cellular immune responses to human visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Vaccines for leishmaniasis in the fore coming 25 years.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Fractionation of mycobacterial integral membrane proteins by continuous elution SDS-PAGE reveals the immunodominance of low molecular weight subunits for human T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Colorimetric quantitation of trace amounts of sodium lauryl sulfate in the presence of nucleic acids and proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Nitric oxide and macrophage function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Mechanisms of acquired immunity in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Splenic cytokine responses in Indian kala-azar before and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Leishmania vaccines: progress and problems.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Leishmaniasis vaccination: targeting the source of infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Second-generation vaccines against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Onchocerca volvulus glycolytic enzyme fructose-1,6-bisphosphate aldolase as a target for a protective immune response in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Aldolase activity of a Plasmodium falciparum protein with protective properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Cloning, over-expression, purification and characterization of Plasmodium falciparum enolase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Cloning and characterisation of strain-specific transcripts encoding triosephosphate isomerase, a candidate vaccine antigen from Schistosoma japonicum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

HSP27 and HSP70: potentially oncogenic apoptosis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Expression of calreticulin P-domain results in impairment of secretory pathway in Leishmania donovani and reduced parasite survival in macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Identification of a disulfide isomerase protein of Leishmania major as a putative virulence factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Heterogeneity of wild Leishmania major isolates in experimental murine pathogenicity and specific immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

Silver staining of proteins in polyacrylamide gels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Enolase antigen, mannan antigen, Cand-Tec antigen, and beta-glucan in patients with candidemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant Leishmania Hsp90 and Hsp70 are recognized by sera from visceral leishmaniasis patients but not Chagas' disease patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.08.021

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33365473&oldid=1979585599"